The Leeds Vascular Institute Leeds General Infirmary Leeds UK.
The Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine University of Leeds Leeds UK.
BJS Open. 2019 May 17;3(5):572-584. doi: 10.1002/bjs5.50178. eCollection 2019 Oct.
Juxtarenal abdominal aortic aneurysms pose a significant challenge whether managed endovascularly or by open surgery. Fenestrated endovascular aneurysm repair (FEVAR) is now well established, but few studies have compared it with open surgical repair (OSR). The aim of this systematic review was to compare short- and long-term outcomes of FEVAR and OSR for the management of juxtarenal aortic aneurysms.
A literature search was conducted of the Ovid Medline, EMBASE and PubMed databases. Reasons for exclusion were series with fewer than 20 patients, studies published before 2007 and those concerning ruptured aneurysms. Owing to variance in definitions, the terms 'juxta/para/suprarenal' were used; thoracoabdominal aortic aneurysms were excluded. Primary outcomes were 30-day/in-hospital mortality and renal insufficiency. Secondary outcomes included major complication rates, rate of reintervention and rates of endoleak.
Twenty-seven studies were identified, involving 2974 patients. Study designs included 11 case series, 14 series within retrospective cohort studies, one case-control study and a single prospective non-randomized trial. The pooled early postoperative mortality rate following FEVAR was 3·3 (95 per cent c.i. 2·0 to 5·0) per cent, compared with 4·2 (2·9 to 5·7) per cent after OSR. After FEVAR, the rate of postoperative renal insufficiency was 16·2 (10·4 to 23·0) per cent, compared with 23·8 (15·2 to 33·6) per cent after OSR. The major early complication rate following FEVAR was 23·1 (16·8 to 30·1) per cent 43·5 (34·4 to 52·8) per cent after OSR. The rate of late reintervention after FEVAR was higher than that after OSR: 11·1 (6·7 to 16·4) 2·0 (0·6 to 4·3) per cent respectively.
No significant difference was noted in 30-day mortality; however, FEVAR was associated with significantly lower morbidity than OSR. Long-term durability is a concern, with far higher reintervention rates after FEVAR.
肾上腹主动脉瘤无论是采用腔内还是开放手术治疗都极具挑战性。覆膜支架腔内修复术(fenestrated endovascular aneurysm repair,FEVAR)已经成熟,但很少有研究将其与开放手术修复(open surgical repair,OSR)进行比较。本系统评价旨在比较 FEVAR 和 OSR 治疗肾上腹主动脉瘤的短期和长期结果。
对 Ovid Medline、EMBASE 和 PubMed 数据库进行文献检索。排除标准为病例系列少于 20 例、发表于 2007 年以前的研究以及破裂性动脉瘤的研究。由于定义上的差异,使用了“肾上/旁/上”等术语;胸主动脉腹主动脉瘤被排除在外。主要结局为 30 天/住院内死亡率和肾功能不全。次要结局包括主要并发症发生率、再干预率和内漏发生率。
共确定了 27 项研究,涉及 2974 例患者。研究设计包括 11 个病例系列、14 个回顾性队列研究系列、1 个病例对照研究和 1 个前瞻性非随机试验。FEVAR 术后早期死亡率为 3.3%(95%可信区间 2.0%至 5.0%),OSR 为 4.2%(2.9%至 5.7%)。FEVAR 术后肾功能不全发生率为 16.2%(10.4%至 23.0%),OSR 为 23.8%(15.2%至 33.6%)。FEVAR 术后早期主要并发症发生率为 23.1%(16.8%至 30.1%),OSR 为 43.5%(34.4%至 52.8%)。FEVAR 术后晚期再干预率高于 OSR:分别为 11.1%(6.7%至 16.4%)和 2.0%(0.6%至 4.3%)。
30 天死亡率无显著差异,但 FEVAR 与 OSR 相比,发病率显著降低。长期耐久性是一个问题,FEVAR 后再干预率要高得多。